Instagram Facebook LinkedIn YouTube  
 
Email not displaying correctly? View it in your browser.
 
Issue 1,841: November 12, 2025  
Top Stories
 
Immunize​.org Website and Clinical Resources 
 
Featured Resources
 
Notable Publications
 
 Upcoming Events
 
Top Stories

CDC publishes updated interim clinical considerations for use of 2025–26 COVID-19 vaccines in the United States

CDC posted Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States on November 4, incorporating changes to COVID-19 vaccine recommendations adopted at the September ACIP meeting. A summary of notable content appears below.

  • The COVID-19 vaccination recommendations were updated to reflect individual-based decision-making (also known as shared clinical decision-making) for people age 6 months and older, including vaccination during pregnancy.
  • Pfizer-BioNTech COVID-19 vaccine (Comirnaty) is no longer authorized for children age 6 months–4 years. The only FDA-approved COVID-19 vaccine available for this age group is Moderna (Spikevax).
  • An initial series of Moderna's Spikevax is now recommended only for children age 6 through 23 months (2024–25 season recommendations included an initial series for children age 6 through 59 months).
  • An initial 2-dose series is no longer recommended for previously unvaccinated recipients of the Sanofi-Novavax vaccine (Nuvaxovid).
  • An initial series of COVID-19 vaccine remains recommended for all previously unvaccinated people with moderate or severe immunocompromise.
  • A second dose of a 2025–26 COVID-19 vaccine is recommended for adults age 65 years or older 6 months after the first 2025–26 dose. 

In coming days, Immunize​.org will release updated standing orders templates for COVID-19 vaccination, in addition to an updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools.

New and updated materials will be announced in IZ Express and posted on the What’s New on Immunize​.org web page. The Ask the Experts: COVID-19 web page will be updated in the weeks after the release of these materials.

Related Links


Immunize​.org updates "Vaccines Work!" with table showing how rates of each vaccine-preventable disease fell after introduction of vaccination

Immunize​.org updated its popular Vaccines Work! 1-page document with revised CDC data on how much rates of each vaccine-preventable disease dropped after introduction of routine vaccination. 

Related Links

Back to top

Routine HepB birth dose policies protect babies. Immunize​.org’s Hepatitis B Birth Dose Honor Roll recognizes 593 institutions, including two renewing honorees. 

HepB vaccination is extremely effective during infancy, protecting about 98% of healthy, term infants. Transmission of hepatitis B virus (HBV) during infancy results in chronic, lifelong infection for about 9 in 10 babies, with one in four of them suffering cirrhosis or liver cancer in adulthood. Vaccination and use of hepatitis B immune globulin (HBIG) for infants born to both HBV test-positive mothers and mothers of unknown status reduces the risk of HBV transmission by 94%; vaccination alone, given on the day of birth, reduces the risk by 75%. 
 
To ensure no child is missed, the HepB birth dose was first recommended for all U.S.-born infants in 2005. ACIP specified in 2016 that the vaccine should be given within the first 24 hours of life, to better assure protection of any newborn with an unrecognized exposure to HBV. In 2013, Immunize​.org started recognizing hundreds of birthing institutions that established policies and practices ensuring that at least 90% of infants born receive HepB before going home. These policies and practices represent a critical safety net to protect newborns from the lifelong consequences of early HBV infection. 
 
Immunize​.org is pleased to renew two institutions’ Hepatitis B Birth Dose Honor Roll status, retaining their standing among 593 honorees. The birthing institutions are listed below with their reported hepatitis B birth dose coverage rates in parentheses. 

  • Odessa Regional Medical Center, Odessa, TX (90%) (3 years) 
  • Shannon Medical Center, San Angelo, TX (90%) (10 years) 

The Honor Roll includes birthing institutions from 50 states, the District of Columbia, American Samoa, Guam, Puerto Rico, Northern Mariana Islands, and U.S. military hospitals overseas.   



The Honor Roll is a key part of Immunize​.org’s initiative urging the nation’s hospitals to Give Birth to the End of Hep B. The How to Apply web page provides information on the criteria for inclusion in the Hepatitis B Birth Dose Honor Role and the application form.
 
Honorees receive an 8.5" x 11" color certificate suitable for printing and framing. Their acceptance is announced through Immunize​.org’s social media channels and to IZ Expresss readers.   
   
Please visit the Hepatitis B Birth Dose Honor Roll web page that lists these institutions and celebrates their vigorous efforts to protect infants from perinatal hepatitis B transmission. 

Related Immunize​.org Resources 


“Hepatitis B Infection Diagnosed After Vaccination”: how this could happen explained in a 1-minute video, part of the Ask the Experts Video Series on YouTube

This week, our featured episode from the Ask the Experts Video Series is titled Hepatitis B Infection Diagnosed After Vaccination. While a breakthrough hepatitis B infection can happen, it is very uncommon in an otherwise healthy young adult. On the other hand, infection before vaccination is a more likely scenario, especially if vaccination is not routinely completed in infancy. This fact underscores the importance of triple panel screening of every adult, regardless of vaccination history.

The 1-minute video is available on our YouTube channel, along with our full collection of quick video answers to popular Ask the Experts questions.

Like, follow, and share Immunize​.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.


Vaccines in the news

These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.


Immunize​.org Website and Clinical Resources

Spotlight on the website: Travel Vaccine resources 

This week’s Spotlight features our Travel Vaccines sections on both the Immunize​.org and VaccineInformation.org sites. These resources provide easy access to reliable travel vaccination guidance for healthcare professionals and the public. 

Immunize​.org: Travel Vaccines

Found under the Vaccines & VISs tab, this section links to key travel vaccination resources from CDC and nongovernmental experts, such as the International Society of Travel Medicine. 

 

Scroll down the page to see a disease directory that lists preventable diseases with travel vaccination considerations. Links take you directly to the travel information section of vaccine-specific Vaccine A–Z pages on our website. 

 

VaccineInformation.org: Travel Vaccine Basics 

At VaccineInformation.org, our Travel Vaccine Basics main page is located under the Vaccine Basics tab. It provides links to plain-language travel vaccination resources from CDC and nongovernmental experts. Direct links to popular resources on the CDC Travelers’ Health website and CDC Travel Health Notices make it easy to find trustworthy advice. 

 

Below the Key Resources section, a Disease Directory lists vaccine-preventable diseases with travel vaccination considerations. Each of the disease pages listed on the Travel Vaccine Basics main page contains disease-specific travel information.
 
Within the Where to Get Vaccinated tab of the Vaccine Basics section, we provide a section with links to assist travelers looking for a travel vaccine clinic. 

 

Use our Travel Vaccine resources on both Immunize​.org and VaccineInformation.org to connect to trustworthy travel vaccination information.


Recap: Immunize​.org updates three print-ready QR code tables that give quick VIS access

Immunize​.org updated three of its printable QR code tables for clinic use. The QR codes in these tables, when scanned (or clicked), link directly to a VIS. The document changes did not alter the VIS QR codes on the current documents, so there is no need to change the QR codes you are using now to continue accessing current VISs. The updates include:


Featured Resources

Needle anxiety is common at any age. Use Immunize​.org’s clinical resources to offer a positive vaccination experience.

In Clinical Resources: Improving the Vaccination Experience, Immunize​.org provides print and video tools to create a positive vaccination experience and ease injection anxiety in children and adults. Links to additional resources from trusted partner organizations are also provided.

The web page links to eight printable resources on addressing vaccination anxiety (four for providers, four for recipients—also available in Spanish), two in-depth webinars, and six brief videos (listed below). As with all Immunize​.org resources, these are free to download, link, copy, and share.



The video topics include:

Related Link


Help Immunize​.org reach more vaccinators through your social media networks. Follow us and share our posts on Facebook, Instagram, and LinkedIn!

Immunize​.org offers a social media program to highlight our educational resources for a widespread audience of vaccinators. Our social media channels now feature recently updated printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators. Please view and share our most popular social media feature, the Ask the Experts Video Series.

Like, follow, and share Immunize​.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:


Notable Publications

“Vascular and Inflammatory Diseases After COVID-19 Infection and Vaccination in Children and Young People in England: A Retrospective, Population-Based Cohort Study Using Linked Electronic Health Records” published in Lancet Child and Adolescent Health

In its December issue, Lancet Child and Adolescent Health published Vascular and Inflammatory Diseases After COVID-19 Infection and Vaccination in Children and Young People in England: A Retrospective, Population-Based Cohort Study Using Linked Electronic Health Records. The study found that infection of children and young people with the COVID-19 virus posed a far greater risk of thromboembolism, myocarditis, or related disorders than did receipt of COVID-19 vaccine. Portions of the research-in-context section appear below.

In summary, first COVID-19 infection was associated with rare but serious health risks that persisted for many months, whereas the elevated risks observed after first vaccination were confined to the early post-vaccination period and were substantially lower than the risks following COVID-19 infection. These contrasting findings support continued vaccination in children and young people as an effective public health strategy to mitigate the more frequent and persistent risks associated with SARS-CoV-2 infection. Policy makers and health-care providers can use these results to support informed discussions with caregivers regarding the relative safety profiles of infection and vaccination.


“Preventive Effect of Vaccination on Long COVID in Adolescents with SARS-CoV-2 Infection” published in Vaccine

In its December 5 issue, Vaccine published Preventive Effect of Vaccination on Long COVID in Adolescents with SARS-CoV-2 Infection. Portions of the abstract appear below.

Vaccinated (n = 724) and unvaccinated (n = 507) adolescents were matched on sex, infection date, and enrollment date. The risk of LC [Long COVID] was 36 % lower . . . in vaccinated compared to unvaccinated participants. . . .

Vaccination reduces the risk of LC. Given the profound impact LC can have on the health and well-being of adolescents and the limited availability of treatments during this developmental stage, this supports vaccination as a strategy for preventing LC by demonstrating an important secondary prevention effect.



Back to top


Upcoming Events

Today! Virtual: Register for Immunize​.org Website Office Hours. Join a 30-minute discussion about our new travel vaccine content on November 12 at 4:00 p.m. (ET) or November 13 at 12:00 p.m. (ET). Recorded sessions archived.

To learn simple tips and tricks for using our websites efficiently, please register for our next set of Website Office Hours on Wednesday, November 12, at 4:00 p.m. (ET) or Thursday, November 13, at 12:00 p.m. (ET). The same content will be covered in both sessions. 

 

We will open each 30-minute session with a short, live demonstration on navigating our Travel Vaccines website sections on Immunize​.org and VaccineInformation​.org. You can submit questions when you register or live on Zoom during the session.

Register today for Immunize​.org Website Office Hours (content is the same for both): 

The archive of previous Website Office Hours content is posted at Immunize​.org’s "Webinars & Videos" page. 

Mark your calendar for future Immunize​.org Website Office Hours. 


Virtual: Wayne State University hosts webinar titled "Strategic Messaging for Vaccine Hesitancy: MMR Vaccines and Hesitancy" on November 13 at 3:30 p.m. (ET); CE credit offered

Wayne State University’s Center for Emerging & Infectious Diseases will host a webinar titled Strategic Messaging for Vaccine Hesitancy: MMR Vaccines and Hesitancy at 3:30 p.m. (ET) on November 13. This webinar will address misconceptions and natural immunity beliefs, present four decades of safety data, discuss culturally tailored approaches for diverse patient populations, and explore national and local trends in measles disease and MMR immunization.

The Wayne State University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 credit.

Register for the webinar.

Back to top

Virtual: North Dakota State University Center for Immunization Research and Education hosts webinar titled “The National Vaccine Injury Compensation Program: Continuity and Change” on November 20 at 1:00 p.m. (ET); CE credit offered

The North Dakota State University Center for Immunization Research and Education will host a webinar titled The National Vaccine Injury Compensation Program: Continuity and Change, at 1:00 p.m. (ET) on November 20. The speaker is Dorit Rubinstein Reiss, LLB, PhD, professor of law at the University of California College of the Law, San Francisco.

This webinar will explore the National Vaccine Injury Compensation Program's (VICP) origins, structure, and role in maintaining public confidence in vaccination. Dr. Reiss will also describe the ongoing discussions about proposed reforms and their potential implications for the program’s effectiveness and fairness.

Free CME and CPE will be provided to live attendees.

Register for the webinar.


Virtual: Children’s Hospital of Philadelphia hosts Current Issues in Vaccines webinar titled “The Hepatitis B Birth Dose Revisited” on December 3 at 12:00 p.m. (ET); CE credit offered

The Vaccine Education Center (VEC) at Children's Hospital of Philadelphia (CHOP) will present a 1-hour webinar titled The Hepatitis B Birth Dose Revisited beginning at 12:00 p.m. (ET) on December 3. Part of its Current Issues in Vaccines series, the webinar will feature Paul Offit, MD, director of the VEC.

Free continuing education credits (CME, CEU, and CPE) will be available for both the live and archived events.

Register for the webinar.


For more upcoming events, visit our Calendar of Events.
Editorial Information

Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Gräbenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
 
About IZ Express
Immunize​.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize​.org is the source of the material and provide a link to this issue.

IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize​.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN: 2771-8085






This email was sent to [email protected]
why did I get this?    unsubscribe from this list    update subscription preferences
Immunize.org · 2136 Ford Parkway · Suite 5011 · Saint Paul, MN 55116 · USA